Antibody-drug conjugate development: opening windows for EGFR-mutant EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancers?

被引：0
|
作者：
Hida, Toyoaki [1 ]
机构：
[1] Cent Japan Int Med Ctr, Lung Canc Ctr, Minokamo, Gifu 5058510, Japan
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2024年 / 13卷 / 04期
关键词：
Antibody-drug conjugates (ADCs); EGFR-tyrosine kinase inhibitor resistance (EGFR-TKI resistance); MET gene alterations; biparatopic antibodies (biparatopic Abs); bystander effect; PHASE; 1/2; EFFICACY; REGN5093-M114; TOLERABILITY; COMBINATION;
D O I：
10.21037/tlcr-24-100
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：936 / 939
页数：4
相关论文
共 50 条
  • [31] Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer
    Digumarthy, Subba R.
    Mendoza, Dexter P.
    Padole, Atul
    Chen, Tianqi
    Peterson, P. Gabriel
    Piotrowska, Zofia
    Sequist, Lecia, V
    CANCERS, 2019, 11 (09)
  • [32] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Kyoko Otsuka
    Akito Hata
    Jumpei Takeshita
    Chiyuki Okuda
    Reiko Kaji
    Katsuhiro Masago
    Shiro Fujita
    Nobuyuki Katakami
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 835 - 841
  • [33] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Otsuka, Kyoko
    Hata, Akito
    Takeshita, Jumpei
    Okuda, Chiyuki
    Kaji, Reiko
    Masago, Katsuhiro
    Fujita, Shiro
    Katakami, Nobuyuki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 835 - 841
  • [34] EGFR tyrosine kinase inhibitor in advanced non-small cell lung cancer with wild-type EGFR
    Wang, Z.
    Wu, Y. L.
    Yang, J.
    Wang, B.
    Huang, Y.
    Zhou, Q.
    Xu, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] Circulating Tumor Cells Predict Prognosis Following Tyrosine Kinase Inhibitor Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Patients
    Yang, Baohong
    Qin, Aiying
    Zhang, Kongyuan
    Ren, Haipeng
    Liu, Shuzhen
    Liu, Xiaolei
    Pan, Xiangpo
    Yu, Guohua
    ONCOLOGY RESEARCH, 2017, 25 (09) : 1601 - 1606
  • [36] Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy
    Liao, Bin-Chi
    Lin, Chia-Chi
    Lee, Jih-Hsiang
    Yang, James Chih-Hsin
    LUNG CANCER, 2017, 110 : 7 - 13
  • [37] EGFR Tyrosine Kinase Inhibitor and Chemotherapy in EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Nishino, Kazumi
    Kimura, Madoka
    Inoue, Takako
    Uchida, Junji
    Kumagai, Toru
    Imamura, Fumio
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S526 - S526
  • [38] Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer
    Lu, Xiaotong
    Wang, Jingbo
    Wang, Chunyu
    Liang, Jun
    Zhou, Zongmei
    Chen, Dongfu
    Feng, Qinfu
    Xiao, Zefen
    Hui, Zhouguang
    Lu, Jima
    Zhang, Tao
    Liu, Wenyang
    Wang, Jianyang
    Wang, Xin
    Deng, Lei
    Zhai, Yirui
    Bi, Nan
    Wang, Luhua
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2022, 16
  • [39] Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
    Xia, Jinjing
    Bai, Hao
    Yan, Bo
    Li, Rong
    Shao, Minhua
    Xiong, Liwen
    Han, Baohui
    ONCOTARGET, 2017, 8 (65) : 108522 - 108533
  • [40] Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
    Yonesaka, Kimio
    Iwama, Eiji
    Hayashi, Hidetoshi
    Suzuki, Shinichiro
    Kato, Ryoji
    Watanabe, Satomi
    Takahama, Takayuki
    Tanizaki, Junko
    Tanaka, Kaoru
    Takeda, Masayuki
    Sakai, Kazuko
    Azuma, Koichi
    Chiba, Yasutaka
    Atagi, Shinji
    Nishio, Kazuto
    Okamoto, Isamu
    Nakagawa, Kazuhiko
    SCIENTIFIC REPORTS, 2019, 9 (1)
12345